Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata

October 2019 in “ Dermatology and therapy ”

Ana Montilla, Francisco Gómez-García, Pedro Jesús Gómez-Arias, Jesús Gay-Mimbrera, Jorge Hernández-Parada, Beatriz Isla-Tejera, Juan Ruano

JAK/STAT pathway alopecia areata tofacitinib ruxolitinib

TLDR Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

The document reviewed the use of drugs targeting the JAK/STAT pathway for treating atopic dermatitis (AD), vitiligo, and alopecia areata (AA), diseases where this pathway plays a role in inflammation. As of April 2019, no drugs targeting this pathway had been approved for dermatological diseases. The review included 96 studies, with 66 on AA, 10 on vitiligo, and 20 on AD. Drugs such as tofacitinib and ruxolitinib were primarily used across all three diseases, with additional drugs tested for AD and AA. Results showed all AD patients improved, while responses in vitiligo and AA patients varied, including some unresponsive cases. The safety profiles of these drugs were generally mild or without adverse events. However, the evidence for the efficacy and safety of these drugs was still considered to be of low quality.

View this study on europepmc.org →

Discuss this study in the Community →

Cited in this study

65 / 65 results

research The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review

19 citations , August 2019 in “Dermatologic therapy”

Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.

research Alopecia Universalis: Partial Response to Tofacitinib

1 citations , August 2019 in “Medicina Clínica (English Edition)”

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , April 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

research Tofacitinib Therapy for Children with Severe Alopecia Areata

39 citations , April 2019 in “Journal of the American Academy of Dermatology”

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata

32 citations , April 2019 in “JAAD case reports”

JAK inhibitors helped treat hair loss in two people with Down syndrome.

research Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients

17 citations , February 2019 in “Dermatologic Therapy”

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

research Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children

40 citations , February 2019 in “Journal of the American Academy of Dermatology”

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

research Ruxolitinib for the Treatment of Severe Alopecia Areata

37 citations , February 2019 in “Journal of the American Academy of Dermatology”

Ruxolitinib can help regrow hair in severe alopecia areata.

research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature

17 citations , January 2019 in “Journal of cutaneous medicine and surgery”

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata

11 citations , January 2019 in “Journal of the European Academy of Dermatology and Venereology”

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

research Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes

24 citations , November 2018 in “JAAD Case Reports”

A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.

research Therapeutic Synergy Between Contact Dermatitis from a Wig-Fixing Device and Tofacitinib on Alopecia Areata

4 citations , September 2018 in “The Journal of Dermatology”

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

research JAK Inhibitors for Treatment of Alopecia Areata

63 citations , September 2018 in “The journal of investigative dermatology/Journal of investigative dermatology”

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology

63 citations , September 2018 in “Journal of the American Academy of Dermatology”

Topical JAK inhibitors may help treat some skin conditions but need more research.

research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study

49 citations , August 2018 in “International Journal of Dermatology”

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

research An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review

5 citations , August 2018 in “PubMed”

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

research Balance of Tofacitinib Efficacy and Disease Flare in the Treatment of Alopecia Universalis: A Case Report and Review of the Literature

9 citations , August 2018 in “JAAD Case Reports”

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , July 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

53 citations , July 2018 in “Drug design, development and therapy”

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

research Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor

16 citations , July 2018 in “JAAD case reports”

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

research Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis

49 citations , June 2018 in “Journal of the American Academy of Dermatology”

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

research Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib

9 citations , May 2018 in “Journal of Dermatological Treatment”

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

research Molecular Correlation With Clinical Outcomes in an Open Label Clinical Trial of Oral Tofacitinib in Patients With Alopecia Areata

1 citations , May 2018 in “Journal of Investigative Dermatology”

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations , February 2018 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

research Emerging Drugs for Alopecia Areata: JAK Inhibitors

20 citations , January 2018 in “Expert opinion on emerging drugs”

JAK inhibitors may soon be a safe and effective treatment for alopecia areata.

$Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study$

research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study

11 citations , January 2018 in “Acta dermato-venereologica”

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

24 citations , January 2018 in “International Journal of Trichology”

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

$Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series$

research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series

44 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

research Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo

37 citations , October 2017 in “Clinical and Experimental Dermatology”

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient

22 citations , September 2017 in “Skin appendage disorders”

Ruxolitinib helped a man regrow his beard after years of hair loss.

research Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series

16 citations , July 2017 in “Rheumatology and Therapy”

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata

83 citations , July 2017 in “Journal of the American Academy of Dermatology”

Topical JAK inhibitors may help children with alopecia areata regrow hair.

research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata

30 citations , June 2017 in “Journal of cutaneous medicine and surgery”

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

research Treatment of Alopecia Areata With Tofacitinib

78 citations , June 2017 in “JAMA Dermatology”

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

research Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment

8 citations , May 2017 in “Singapore Medical Journal”

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

research An Open Label Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata

2 citations , May 2017 in “Journal of Investigative Dermatology”

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

research Treatment of Severe Alopecia Areata with the Oral Janus Kinase Inhibitor, Tofacitinib: A Retrospective Chart Review

1 citations , May 2017 in “Journal of Investigative Dermatology”

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

research Janus Kinase Inhibitors in Dermatology: A Systematic Review

116 citations , April 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors help with skin conditions but need more research on dosing and safety.

research Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis

49 citations , April 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , April 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

research Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring

25 citations , March 2017 in “International Journal of Dermatology”

Ruxolitinib effectively and safely regrows hair in alopecia patients.

research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature

40 citations , January 2017 in “Journal of Dermatological Treatment”

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , January 2017 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Alopecia Universalis Unresponsive to Treatment with Tofacitinib: Report of a Case with a Brief Review of the Literature

8 citations , January 2017 in “Dermatology online journal”

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis

16 citations , January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)”

A patient with complete hair loss regrew all her hair using tofacitinib.

$Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman$

research Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman

24 citations , January 2017 in “Acta dermato-venereologica”

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

research Reversal of Alopecia Universalis by Tofacitinib: A Case Report

14 citations , November 2016 in “Annals of Internal Medicine”

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report

26 citations , October 2016 in “Case Reports in Dermatology”

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers

70 citations , July 2016 in “Experimental Dermatology”

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

research Alopecia Areata and Health-Related Quality of Life: A Systematic Review and Meta-Analysis

128 citations , July 2016 in “British Journal of Dermatology”

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

research Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients

51 citations , June 2016 in “Journal of the European Academy of Dermatology and Venereology”

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

research An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata

3 citations , May 2016 in “Journal of Investigative Dermatology”

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

39 citations , April 2016 in “Case Reports in Dermatology”

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

research Topical Ruxolitinib for the Treatment of Alopecia Universalis

96 citations , April 2016 in “JAMA dermatology”

research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis

41 citations , April 2016 in “JAMA Dermatology”

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata

157 citations , February 2016 in “Journal of the American Academy of Dermatology”

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations , April 2015 in “EBioMedicine”

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , December 2014 in “Journal of Investigative Dermatology”

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Alopecia in the United States: Outpatient Utilization and Common Prescribing Patterns

46 citations , August 2007 in “Journal of the American Academy of Dermatology”

Alopecia areata causes significant emotional distress, including high rates of depression and anxiety.

research Familial Aggregation of Alopecia Areata

295 citations , April 2006 in “Journal of the American Academy of Dermatology”

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

3 / 3 results

research Resistant Alopecia Areata Treated with Tofacitinib

1 citations , January 2022 in “International Journal of Trichology”